User menu

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Bibliographic reference Ravandi, Farhad ; Ritchie, Ellen K ; Sayar, Hamid ; Lancet, Jeffrey E ; Craig, Michael D ; et. al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.. In: The Lancet Oncology, Vol. 16, no.9, p. 1025-1036 (2015)
Permanent URL http://hdl.handle.net/2078.1/181308